Severe cutaneous adverse reaction

This Phase 2 trial tests whether small interfering RNA (siRNA) microneedle patches can improve the appearance of earlobe keloid scars after laser surgery. About 158 adults with earlobe keloids will receive either standard steroid injections alone or steroid injections plus the si…

This study tests whether a genetic test can prevent rare but severe skin reactions caused by the common gout drug allopurinol. About 228 Vietnamese adults with gout will either get the test before treatment or receive standard care. Those with a high-risk gene will take a differe…

This trial tests whether a single injection of polynucleotides, a solution called PLINEST One, can improve scar quality after thyroid or parathyroid surgery. Adults aged 40 to 60 having neck surgery for the first time will receive either the polynucleotide injection or a saline p…

This study tests whether a procedure called dermabrasion, which sands the skin, can improve the appearance of scars from free flap reconstruction in the head and neck. Forty adults who had flap surgery at least three months ago will have half their scar treated and half left alon…

This trial asks whether combining silicone sheets with standard pressure garments can improve the appearance and quality of limb scars better than pressure garments alone. About 60 adults aged 18-65 with scars from injury or surgery will receive either the combined treatment or p…

This study tests whether a topical eye drop called timolol can help surgical wounds on the scalp heal faster and look better after Mohs surgery. About 40 adults will either use timolol or standard wound care. Researchers will check healing and scar appearance at 4, 8, and 12 week…

This phase 2 trial tests whether verteporfin, a drug injected into the skin during tummy tuck surgery, can reduce scar formation. Twelve adults will receive different doses of verteporfin and a placebo in separate parts of their surgical wound. Researchers will compare scar appea…

This study will test the safety of a new biologic drug called stapokibart, given as a shot, in 400 adults with seasonal allergic rhinitis (SAR). Participants are already prescribed the drug by their doctor. The main goal is to track any side effects. This is an open-label study, …